Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2023-44308
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Description
Open redirect vulnerability in adaptive media administration page in Liferay DXP 2023.Q3 before patch 6, and 7.4 GA through update 92 allows remote attackers to redirect users to arbitrary external URLs via the _com_liferay_adaptive_media_web_portlet_AMPortlet_redirect parameter.
Source: NVD (National Vulnerability Database)
CVSS Information
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N
Source: NVD (National Vulnerability Database)
Vulnerability Type
指向未可信站点的URL重定向(开放重定向)
Source: NVD (National Vulnerability Database)
Vulnerability Title
Liferay DXP 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
Liferay DXP是美国Liferay公司的一套数字化体验协作平台。 Liferay DXP 存在安全漏洞,该漏洞源于存在开放重定向漏洞,允许远程攻击者通过 _com_liferay_adaptive_media_web_portlet_AMPortlet_redirect 参数将用户重定向到任意外部 URL。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
LiferayDXP 2023.q3.1 ~ 2023.q3.5 -
II. Public POCs for CVE-2023-44308
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2023-44308
Please Login to view more intelligence information
IV. Related Vulnerabilities
V. Comments for CVE-2023-44308

No comments yet


Leave a comment